Global life-long health benefits of repression of hypothalamic NPY system by central leptin gene therapy

Current Topics in Medicinal Chemistry

Volumn 7, Issue 17, 2007, Pages 1675-1681

  Kalra, Satya P ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bone growth; Diabetes; Hypothalamic NPY; Leptin gene therapy; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; GHRELIN; LEPTIN; NEUROPEPTIDE Y; PARVOVIRUS VECTOR; SOMATOMEDIN C;

BONE GROWTH; DIABETES MELLITUS; DYSLIPIDEMIA; ENERGY EXPENDITURE; GENE THERAPY; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; LIFESPAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; VIRAL GENE DELIVERY SYSTEM; WEIGHT GAIN;

ANIMALS; GENE THERAPY; HUMANS; HYPOTHALAMUS; INSURANCE BENEFITS; LEPTIN; LIFE EXPECTANCY; NEUROPEPTIDE Y; OBESITY;

EID: 36248961170     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607782340993     Document Type: Review

References (105)

1. Clark, J. T.; Kalra, P. S.; Crowley, W. R.; Kalra, S. P. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology, 1984, 115, 427-429.
2. Friedman, J. M.; Halaas, J. L. Leptin and the regulation of body weight in mammals. Nature, 1998, 395, 763-770.
3. Kalra, S. P.; Dube, M. G.; Pu, S.; Xu, B.; Horvath, T. L.; Kalra, P. S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev., 1999, 20, 68-100.
4. Kalra, S. P.; Bagnasco, M.; Otukonyong, E. E.; Dube, M. G.; Kalra, P. S. Rhythmic, reciprocal ghrelin and lentin signaling: new insight in the development of obesity. Regul. Pept., 2003, 111, 1-11.
5. Murphy, K. G.; Bloom, S. R. Gut hormones and the regulation of energy homeostasis. Nature, 2006, 444, 854-859.
6. Rosen, E. D.; Spiegelman, B. M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature, 2006, 444, 847-853.
7. Flegal, K. M.; Graubard, B. I.; Williamson, D. F.; Gail, M. H. Excess deaths associated with underweight, overweight, and obesity. JAMA, 2005, 293, 1861-1867.
8. Despres, J. P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature, 2006, 444, 881-887.
9. Kahn, S. E.; Hull, R. L.; Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444, 840-846.
10. Bray, G. A.; Greenway, F. L. Current and potential drugs for treatment of obesity. Endocr. Rev., 1999, 20, 805-875.
11. Kalra, S. P. Circumventing leptin resistance for weight control. Proc. Natl. Acad. Sci. USA, 2001, 98, 4279-4281.
12. Kalra, S. P.; Kalra, P. S. Viral vectors as probes to decipher brain circuitry for weight control. Trends Endocrinol. Metab., 2001, 12, 377-378.
13. Kalra, P. S.; Kalra, S. P. Obesity and Metabolic Syndrome: Longterm benefits of central leptin gene therapy. In: Prous, J. R. (Ed.), Drugs of Today, vol.38. Prous Science, Barcelona, Spain, 2002, pp. 745-757.
14. Kalra, S. P.; Kalra, P. S. Keeping obesity and metabolic syndrome at bay with central leptin and cytokine gene therapy. In: Hamilton, I. (Ed.), Current Medicinal Chemistry - Central Nervous System Agent; vol.3. Bentham Science Publishers Ltd., San Francisco, CA, 2003, pp. 189-199.
15. Arvanitakis, Z.; Wilson, R. S.; Bienias, J. L.; Evans, D. A.; Bennett, D. A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol., 2004, 61, 661-666.
16. Correia, M. L. G.; Rahmouni, K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabet. Obes. Metabol., 2006, 8, 603-610.
17. Kalra, S. P.; Dube, M. G.; Kalra, P. S. Continuous intraven-tricular infusion of neuropeptide Y evokes episodic food intake in satiated female rats; effects of adrenalectomy and cholecystokinin. Peptides, 1988, 9, 723-728.
18. Kalra, S. P.; Kalra, P. S. Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine, 2003, 22, 49-55.
19. Kalra, S. P.; Kalra, P. S. Neuropeptide Y: a conductor of the appetite-regulating orchestra in the hypothalamus. In: Kastin, A. J. [Ed.], The Handbook of Biologically Active Peptides, vol.In Press. Academic Press, Burlington, MA. 2006.
20. Kalra, S. P.; Dube, M. G.; Sahu, A.; Phelps, C. P.; Kalra, P. S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl. Acad., Sci. USA, 1991, 88, 10931-10935.
21. Luquet, S.; Perez, F. A.; Hnasko, T. S.; Palmiter, R. D. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science, 2005, 310, 683-685.
22. Segal-Lieberman, G.; Trombly, D. J.; Juthani, V.; Wang, X.; Maratos-Flier, E. NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. Am. J Physiol. Endocrinol. Metab., 2003, 284, E1131-1139.
23. Sindelar, D. K.; Ste Marie, L.; Miura, G. I.; Palmiter, R. D.; McMinn, J. E.; Morton, G. J.; Schwartz, M. W. Neuropeptide Y is required for hyperphagic feeding in response to neuroglucopenia. Endocrinology, 2004, 145, 3363-3368.
24. Gardiner, J. V.; Kong, W. M.; Ward, H.; Murphy, K. G.; Dhillo, W. S.; Bloom, S. R. AAV mediated expression of anti-sense neuropeptide Y cRNA in the arcuate nucleus of rats results in decreased weight gain and food intake. Biochem. Biophys. Res. Commun., 2005, 327, 1088-1093.
25. Bannon, A. W.; Seda, J.; Carmouche, M.; Francis, J. M.; Norman, M. H.; Karbon, B.; McCaleb, M. L. Behavioral characteri-zation of neuropeptide Y knockout mice. Brain Res., 2000, 868, 79-87.
26. Dube, M. G.; Xu, B.; Crowley, W. R.; Kalra, P. S.; Kalra, S. P. Evidence that nouropeptide Y is a physiological signal for normal food intake. Brain Res., 1994, 646, 341-344.
27. Kalra, S. P.; Kalra, P. S. Nutritional infertility: the role of the interconnected hypothalamic neuropeptide Y-galanin-opioid network. Front Neuroendocrinol., 1996, 17, 371-401.
28. Chen, P.; Williams, S. M.; Grove, K. L.; Smith, M. S. Melanocortin 4 receptor-mediated hyperphagia and activation of neuropeptide Y expression in the dorsomedial hypothalamus during lactation. J. Neurosci., 2004, 24, 5091-5100.
29. Dube, M. G.; Kalra, S. P.; Kalra, P. S. The hypothalamic paraventricular nucleus is not essential for orexigenic NPY or anorexigenic melanocortin action. Peptides, 2006, 27, 2239-2248.
30. Dube, M. G.; Xu, B.; Kalra, P. S.; Sninsky, C. A.; Kalra, S. P. Disruption in neuropeptide Y and leptin signaling in obese ventromedial hypothalamic-lesioned rats. Brain Res., 1999, 816, 38-46.
31. Dube, M. G.; Kalra, S. P.; Kalra, P. S. Low abundance of NPY in the hypothalamus can produce hyperphagia and obesity. Peptides. 2007, doi:10.1016/j.peptides.2006.10.017.
32. Pu, S.; Dube, M. G.; Kalra, S. P.; Kalra, P. S. Permanent interruption of information flow between hypothalamus and hindbrain produces obesity accompanied by a selective dark-phase hyperphagia and hyperinsulinemia. Proceedings of the 33rd Annual Society for Neuroscience Meeting, New Orleans, LA. Society for Neuroscience, 2003, pp. W-33, Abs #831.837.
33. Kalra, S. P.; Sahu, A.; Kalra, P. S. Ageing of theneuropep-tidergic signals in rats. J. Reprod. Fertil. Suppl., 1993, 46, 11-19.
34. Xu, B.; Kalra, P. S.; Farmerie, W. G.; Kalra, S. P. Daily changes in hypothalamic gene expression of neuropeptide Y, galanin, proopiomelanocortin, and adipocyte leptin gene expres-sion and secretion: effects of food restriction. Endocrinology, 1999, 140, 2868-2875.
35. Yokosuka, Mc, Dube, M. G.; Kalra, P. S.; Kalra, S. P. The mPVN mediates blockade of NPY-induced feeding by a Y5 receptor antagonist: a c-FOS analysis. Peptides, 2001, 22, 507-514.
36. Yokosuka, M.; Kalra, P. S.; Kalra, S. P. Inhibition of neuropeptide Y [NPY]-induced feeding and c-Fos response in magnocellular paraventricular nucleus by a NPY receptor antagonist: a site of NPY action. Endocrinology, 1999, 140, 4494-4500.
37. Yokosuka, M.; Xu, B.; Pu, S.; Kalra, P. S.; Kalra, S. P. Neural substrates for leptin and neuropeptide Y [NPY] interaction: hypothalamic sites associated with inhibition of NPY-induced food intake. Physiol. Behav., 1998, 64, 331-338.
38. Kalra, P. S.; Dube, M. G.; Xu, B.; Farmerie, W. G.; Kalra, S. P. Neuropeptide Y [NPY] Y, receptor mRNA is upregulated in association with transient hyperphagia and body weight gain: evidence for a hypothalamic site for concurrent development of leptin resistance. J. Neuroendocrinol., 1998, 10, 43-49.
39. Kalra, P. S.; Dube, M. G.; Xu, B.; Kalra, S. P. Increased receptor sensitivity to neuropeptide Y in the hypothalamus may underlie transient hyperphagia and body weight gain. Regul. Pept., 1997, 72, 121-130.
40. Li, B. H.; Xu, B.; Rowland, N. E.; Kalra, S. P. c-fos expression in the rat brain following central administration of neuropeptide Y and effects of food consumption. Brain Res., 1994, 665, 277-284.
41. Asakawa, A.; Inui, A.; Kaga, T.; Yuzuriha, H.; Nagata, T.; Ueno, N.; Makino, S.; Fujimiya, M.; Niijima, A.; Fujino, M. A.; Kasuga, M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology, 2001, 120, 337-345.
42. Chang, G. Q.; Karatayev, O.; Davydova, Z.; Leibowitz, S. F. Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. Endocrinology, 2004, 145, 3904-3912.
43. Kershaw, E. E.; Flier, J. S. Adipose tissue as an endocrine organ. J Clin. Endocrinol. Metab., 2004, 89, 2548-2556.
44. Shintani, M.; Ogawa, Y.; Ebihara, K.; Aizawa-Abe, M.; Miyanaga, F.; Takaya, K.; Hayashi, T.; Inoue, G.; Hosoda, K.; Kojima, M.; Kangawa, K.; Nakao, K. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes, 2001, 50, 227-232.
45. Unger, R. H. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie, 2005, 87, 57-64.
46. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M. L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 2001, 7, 941-946.
47. Berg, A. H.; Combs, T. P.; Scherer, P. E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab., 2002, 13, 84-89.
48. Bonavera, J. J.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Anorectic effects of estrogen may be mediated by decreased neuropeptide- Y release in the hypothalamic paraventricular nucleus. Endocrinology, 1994, 34, 2367-2370.
49. Pu, S.; Dube, M. G.; Kalra, P. S.; P., K. S. Regulation of leptin secretion: Effects of aging on daily patterns of serum leptin and food consumption. Regul. Pept., 2000, 92, 107-111.
50. Sahu, A.; White, J. D.; Kalra, P. S.; Kalra, S. P. Hypothalamic neuropeptide Y gene expression in rats on scheduled feeding regimen. Brain Res. Mol. Brain Res., 1992, 15, 15-18.
51. Ueno, N.; Dube, M. G,; Inui, A.; Kalra, P. S.; Kalra, S. P. Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology, 2004, 145, 4176-4184.
52. Ueno, N.; Inui, A.; Kalra, S. P.; Kalra, P. S. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides, 2006, 27, 2332-2342.
53. Kalra, S. P.; Ueno, N.; Kalra, P. S. Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action. J. Nutr., 2005, 135, 1331-1335.
54. Kalra, S. P.; Kalra, P. S. NPY and Cohorts in Regulating Appetite, Obesity and Metabolic Syndrome: Beneficial Effects of Gene Therapy. Neuropeptides, 2004, 38, 201-211.
55. Farooqi, I. S.; Matarese, G.; Lord, G. M.; Keogh, J. M.; Lawrence, E.; Agwu, C.; Sanna, V.; Jebb, S. A.; Pema, F.; Fontana, S.; Lechler, R. I.; DePaoli, A. M.; O'Rahilly, zS. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest., 2002, 110, 1093-1103.
56. Farooqi, I. S.; O'Rahilly, S. Monogenic obesity in humans. Annu. Rev. Med., 2005, 56, 443-458.
57. Montague, C. T.; Farooqi, I. S.; Whitehead, J. P.; Soos, M. A.; Rau, H.; Wareham, N. J.; Sewter, C. P.; Digby, J. E.; Mohammed, S. N.; Hurst, J. A.; Cheetham, C. H.; Earley,.A. R.; Barnett, A. H.; Prins, J. B.; O'Rabilly, S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature, 1997, 387, 903-908.
58. Dube, M. G.; Beretta, E.; Dhillon, H.; Ueno, N.; Kalra, P. S.; Kalra, S. P. Central leptin gene therapy blocks high fat diet-induced weight gain, hyperleptinemia and hyperinsulinemia: effects on serum ghrelin levels. Diabetes, 2002, 51, 1729-1736.
59. Banks, W. A.; DiPalma, C. R. and Farrell, C. L. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides, 1999, 20, 1341-1345.
60. Banks, W. A.; Kastin, A. J.; Huang, W.; Jaspan, J. B.t; Maness, L. M. Leptin enters the brain by a saturable system independent of insulin. Peptides, 1996, 17, 305-311.
61. Burguera, B.; Couce, M. E.; Curran, G. L.; Jensen, M. D.; Lloyd, R. V.; Cleary, M. P.; Poduslo, J. F. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes, 2000, 49, 1219-1223.
62. Van Heek, M.; Compton, D. S.; France, C. F.; Tedesco, R. P.; Fawzi, A. B.; Graziano, M. P. Sybertz, E. J.; Strader, C. D.; Davis, H. R., Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest., 1997, 99, 385-390.
63. Wang, H.; Storlien, L. H.; Huang, X. F. Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am. J. Physiol. Endocrinol. Metab., 2002, 282, E1352-1359.
64. Kalra, S. P.; Kalra, P. S. Gene transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life-expectancy. Trends Pharmacol. Sci., 2005, 26, 488-495.
65. Kalra, S. P.; Kalra, P. S. Subjugation of hypothalamic NPY and cohorts with central leptin gene therapy alleviates dyslipi-demia, insulin resistance, and obesity for life-time. In: Zukowska, Z. and Feuerstein, G. (Eds.), "NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolic Disorders:Genes, Functions and Therapeutics." Birhauser Verlag Publishing House, Switzerland, 2006, pp. 157-169.
66. Wiesner, G.; Vaz, M.; Collier, G.; Seals, D.; Kaye, D.; Jennings, G.; Lambert, G.; Wilkinson, D.; Esler, M. Leptin is released from the human brain: influence of adiposity and gender. J. Clin. Endocrinol. Metab., 1999, 84, 2270-2274.
67. Wilkinson, M.; Morash, B.; Ur, E. The Brain is a source of leptin. Front Horm. Res., 2000, 26, 106-125.
68. Maness, L. M.; Kastin, A. J.; Farrell, C. L.; Banks, W. A. Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology, 1998, 139, 4556-4562.
69. Carter, B. J.; Burstein, H. Adeno-associated virus and AAV vectors for gene delivery. In: Templeton-Smith, N. [Ed.], Theruapeutics Mechanisms and Strategies. Marcel Dekker, New York, NY, 2004, pp. 71-1011.
70. Chen, G.; Koyama, K.; Yuan, X.; Lee, Y.; Zhou, Y. T.; O'Doherty, R.; Newgard, C. B.; Unger, R. H. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc. Natl. Acad. Sci. USA, 1996, 93, 14795-14799.
71. Keen-Rhinebart, E.; Kalra, S. P.; Kalra, P. S. Leptin Receptor Gene Transfer into the Arcuate Nucleus of Female Fatty Zucker Rats Using Recombinant Adeno-Associated Viral Vectors Stimulates the Hypothalamo-Pituitary-Gonadal Axis. Biol. Reprod., 2004, 71, 266-272.
72. Keen-Rhinehart, E.; Kalra, S. P.; Kalra, P. S. AAV mediated leptin receptor installation improves energy balance and the reproductive status of obese female Koletsky rats. Peptides, 2005, 26, 2567-2578.
73. Dhillon, H. Effects of recombinant adeno-associated virus encoding leptin on body weight regulation and energy homeostasis. University of Florida, http://purl.fcla.edu/fcla/etd/ane5948, Gainesville, FL 2000, pp. 1-171.
74. Dhillon, H.; Ge, Y.; Minter, R. M.; Prima, V.; Moldawer, L. L.; Muzyczka, N.; Zolotukhin, S.; Kalra, P. S.; Kalra, S. P. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul. Pept., 2000, 92, 97-105.
75. Dhillon, H.; Kalra, S. P.; Kalra, P. S. Dose-Dependent Effects of Central Leptin Gene Therapy on Genes That Regulate Body Weight and Appetite in the Hypothalamus. Mol. Ther., 2001, 4, 139-145.
76. bhillon, H.; Kalra, S. P.; Prima, V. Zolotukhin, S.; Scarpace, P. J.; Moldawer, L. L.; Muzyczka, N.; Kalra, P. S. Central Leptin Gene, Therapy Suppresses Body Weight Gain, Adiposity and Serum Insulin Without Affecting Food Consumption in Normal Rats: A Long-Term Study. Regul. Pept., 2001, 99, 69-77.
77. Boghossian, S.; Lecklin, A. H.; Torto, R.; Kalra, P. S.; Kalra, S. P. Suppression of fat deposition for the life time of rodents with gene therapy. Peptides, 2005, 26, 1512-1519.
78. Bagnasco, M.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Evidence for the existence of distinct central appetite and energy expenditure pathways and stimulation of ghrelin as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology, 2002, 143, 4409-4421.
79. Bagnasco, M.; Dube, M. G. Katz, A.; Kalra, P. S.; Kalra, S. P. Leptin expression in hypothalamic PVN reverses dietary obesity and hyperinsulinemia but stimulates ghrelin. Obesity Res., 2003, 11, 1463-1470.
80. Beretta, E.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods. Peptides, 2002, 23, 875-984.
81. Beretta, E.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: Effects on senim ghrelin and appetite-regulating genes. Ped. Res., 2002, 52, 189-198.
82. Lecklin, A. H.; Dube, M. G.; Torto, R.; Kalra, P. S.; Kalra, S. P. Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation. Peptides, 2005, 26, 1176-1187.
83. Boghossian, S.; Lecklin, A.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Increased Leptin Expression in the Dorsal Vagal Complex Suppresses Adiposity without Affecting Energy Intake and Metabolic Hormones. Obesity, 2006, 14, 1003-1009.
84. Kalra, S. P.; Kalra, P. S. To subjugate NPY is to improve the quality of life and live longer. Peptides. Special NPY Issue, 2007, (in Press).
85. Wolden-Hanson, T.; Marck, B. T.; Smith, L.; Matsumoto,A. M. Cross-sectional and longitudinal analysis of age-associated changes in body composition of male Brown Norway rats: association of serum leptin levels with peripheral adiposity. J. Gerontol. A Biol. Sci. Med. Sci., 1999, 54, B99-B107.
86. Yu, B. P.; Masoro, E. J.; Murata, I.; Bertrand, H. A.; Lynd, F. T. Life span study of SPF Fischer 344 male rats fed ad libitum or restricted diets: longevity, growth, lean body mass and disease. J. Gerontol., 1982, 37, 130-141.
87. Torto, R.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Central teptin therapy blocks ovariectomy-induced adiposity. Obesity, 2006, 14, 1312-1319.
88. Otukonyong, E. E.; Dube, M. G.; Torto, R.; Kalra, P. S.; Kalra, S. P. Central Leptin Differentially Modulates Ultradian Secretory Patterns of Insulin, Leptin and Ghrelin Independent of Effects on Food Intake and Body Weight. Peptides, 2005, 26, 2559-2566.
89. Otukonyong, E. E.; Dube, M. G.; Torto, R.; Kalra, P. S.; Kalra, S. P. High fat diet-induced ultradian leptin and insulin hypersecretion and ghrelin is absent in obesity-resistant rats. Obes. Res., 2005, 113, 991-999.
90. Boghossian, S.; Dube, M. G.; Torto, R.; Kalra, P. S.; Kalra, S. P. Hypothalamic clamp on insulin release by leptin-transgene expression. Peptides, 2006, 27, 3245-3254.
91. Buijs, R. M.; Chun, S. J.; Niijima, ~k.; Romijn, H. Li Nagai, K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of fodd intake. J. Comp. Neurol., 2001,431, 405-423.
92. Wang, Z. W.; Zhou, Y. T.; Kakurna, T.; Lee, Y.; Higa, M.; Kalra, S. P.; Dube, M. G.; Kalra, P. S.; Unger, R. H. Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Proc. Natl. Acad. Sci. USA, 1999, 96, 10373-10378.
93. Sved, A. F.; Cano, G.; Card, J. P. Neuroanatomical specificity of the circuits controlling sympathetic outflow to different targets. Clin. Exp. Pharmacol. Physiol., 2001, 28, 115-119.
94. Lin, S.; Boey, D.; Herzog, H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides, 2004, 38, 189-200.
95. Lin, E. J.; Samsbury, A.; Lee, N. J.; Boey, D.; Couzens, M.; Enriquez, R.; Slack, K.; Bland, R.; During, M. J.; Herzog, H. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperohagia and obesity. Endocrinology, 2006, 147, 5094-5101.
96. Wang, J.; Takeuchi, T.; Tanaka, S.; Kubo, S. K.; Kayo, T.; Lu, D.; Takata, K.; Koizumi, A.; Izumi, T. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J. Clin. Invest., 1999, 103, 27-37.
97. Yoshioka, M.; Kayo, T.; Ikeda, T. and Koizumi, A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 [Akita] mutant mice. Diabetes, 1997, 46, 887-894.
98. Chinookoswong, N.; Wang, J. L.; Shi, Z. Q. Leptin restores euglycemia and normalizes glucose turnover in insulin- deficient diabetes in the rat. Diabetes, 1999, 48, 1487-1492.
99. Kalra, S. P. Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge. Endocr. Rev., 1993, 14, 507-538.
100. Chehab, F. F; Lim, M. E.; Lu, R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat. Genet., 1996, 12, 318-320.
101. Boghossian, S.; Ueno, N.; Dube, M. G.; Kalra, P. S.; Kalra, S. P. Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin. Neurobiol Aging. 2007, doi:10.1016/j,neurobiolaging. 2006.08.010.
102. Thomas, T. The complex effects of leptin-on bone metabolism through multiple pathways. Curr. Opin. Pharmacol., 2004, 4, 295-300.
103. Baldock, P. A.; Sainsbury, A.; Couzens, M.; Enriquez, R. F.; Thomas, G. P.; Gardiner, E. M.; Herzog, H. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest., 2002, 109, 915-921.
104. Iwaniec, U. T.; Boghossian, S.; Lapke, P.-D.; Turner, R. T.; Kalra, S. P. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides, 2007, 28, 1012-1019.
105. Tatar, M., Bartke, A.; Antebi, A. The endocrine regulation of aging by insulin-like signals. Science, 2003, 299, 1346-1351.